Olatoyosi M. Odenike

Olatoyosi M. Odenike

Hematology | Oncology
5758 S Maryland Ave
Chicago, IL 60637

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 133 publications

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

Journal: The New England journal of medicine
Published: June 03, 2026

Association of sarcopenia with treatment tolerance in older adults with acute myeloid leukemia using artificial intelligence computed tomography-segmentation and a geriatric assessment.

Association of sarcopenia with treatment tolerance in older adults with acute myeloid leukemia using artificial intelligence computed tomography-segmentation and a geriatric assessment.

Journal: Leukemia
Published: May 16, 2026

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

Journal: Blood
Published: May 04, 2026

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

Journal: American journal of hematology
Published: April 02, 2026

Ruxolitinib and heart failure outcomes among patients with myelofibrosis.

Ruxolitinib and heart failure outcomes among patients with myelofibrosis.

Journal: Leukemia & lymphoma
Published: March 05, 2026

Risk factors associated with high probability of pulmonary hypertension in patients with myeloproliferative neoplasms.

Risk factors associated with high probability of pulmonary hypertension in patients with myeloproliferative neoplasms.

Journal: International journal of hematology
Published: December 02, 2025

Low Serum Cholesterol Is a Biomarker of Advanced Disease and Poor Outcomes in Myeloproliferative Neoplasms.

Low Serum Cholesterol Is a Biomarker of Advanced Disease and Poor Outcomes in Myeloproliferative Neoplasms.

Journal: Blood advances
Published: November 19, 2025

Low serum cholesterol is a biomarker of advanced disease and poor outcomes in myeloproliferative neoplasms.

Low serum cholesterol is a biomarker of advanced disease and poor outcomes in myeloproliferative neoplasms.

Journal: Blood advances
Published: November 19, 2025

Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report.

Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report.

Journal: Blood advances
Published: November 19, 2025

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Journal: Blood advances
Published: November 19, 2025

Echocardiographic high-output heart failure is associated with worse survival among patients with myelofibrosis.

Echocardiographic high-output heart failure is associated with worse survival among patients with myelofibrosis.

Journal: Cardio-oncology (London, England)
Published: November 17, 2025

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

Journal: HemaSphere
Published: October 21, 2025
Showing 1-12 of 133

Last Updated: 09/26/2026